Amalgamated Bank’s Cymabay Therapeutics CBAY Stock Holding History

Amalgamated Bank’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,279	Closed	-$385K	–	2979
2023 Q4	$385K	Buy	16,279 +1,408	+9%	+$25.1K	﹤0.01%	1543
2023 Q3	$222K	Hold	14,871	–	–	﹤0.01%	1752
2023 Q2	$163K	Buy	+14,871	New	+$138K	﹤0.01%	1899
2022 Q2	–	Sell	-8,381	Closed	-$26K	–	3258
2022 Q1	$26K	Buy	+8,381	New	+$26.4K	﹤0.01%	2727
2020 Q2	–	Sell	-12,209	Closed	-$18K	–	1680
2020 Q1	$18K	Buy	12,209 +108	+0.9%	+$181	﹤0.01%	1626
2019 Q4	$24K	Sell	12,101 -30	-0.2%	-$113	﹤0.01%	1824
2019 Q3	$62K	Sell	12,131 -88	-0.7%	-$533	﹤0.01%	1689
2019 Q2	$87K	Buy	+12,219	New	+$138K	﹤0.01%	1704

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Amalgamated Bank's CBAY Position: Q1 2024 in Review

Amalgamated Bank sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 16,279 shares — an estimated $385K sold.

Amalgamated Bank first reported a position in CBAY in Q2 2019 and held it in 8 quarters. The position peaked at $385K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Amalgamated Bank reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Amalgamated Bank sold 16,279 Cymabay Therapeutics shares in Q1 2024, an estimated $385K.
Amalgamated Bank first reported a position in Cymabay Therapeutics in Q2 2019 and held it in 8 quarters.
Amalgamated Bank's Cymabay Therapeutics position peaked at $385K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Amalgamated Bank's 13F filing for Q1 2024, filed 23 Apr 2024.